• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioRestorative Therapies Inc. (Amendment)

    2/7/23 4:42:24 PM ET
    $BRTX
    Managed Health Care
    Health Care
    Get the next $BRTX alert in real time by email
    SC 13G/A 1 brtx_13ga.htm BRTX 13GA

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    BioRestorative Therapies, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    090655606

    (CUSIP Number)
     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is BioRestorative Therapies, Inc., a Delaware corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 40 Marcus Drive, Melville, New York 11747.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the "Investment Manager") and Mr. Sander Gerber ("Mr. Gerber"), who are collectively referred to herein as "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      090655606

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

     
     

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The Investment Manager serves as the investment manager to Hudson Bay Master Fund Ltd., in whose name the securities reported herein were held. As such, the Investment Manager may have been deemed to be the beneficial owner of all shares of Common Stock held by Hudson Bay Master Fund Ltd. Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
     
     

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 7, 2023

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $BRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRTX

    DatePrice TargetRatingAnalyst
    12/1/2021$37.00Buy
    Roth Capital
    More analyst ratings

    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

      – The International Society for Stem Cell Research ("ISSCR") 2025 Annual Meeting is the world's foremost gathering of stem cell and regenerative medicine leaders – – Updated data presented at ISSCR 2025 demonstrates >50% improvement in pain and function in a significant portion of cLDD subjects – – Number of evaluated subjects increases by more than two-fold since last update –– MELVILLE, N.Y., June 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced the presentation of promising pre

      6/13/25 7:45:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

      MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Mr. Lipkins has an accom

      6/10/25 8:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

      – New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma – – BioRestorative to release new clinical data to the public prior to market open on June 13th – MELVILLE, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its

      6/9/25 7:45:00 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on BioRestorative Therapies with a new price target

      Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00

      12/1/21 10:21:36 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      3/6/24 4:34:22 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      2/15/24 4:43:54 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

      SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

      2/15/24 4:40:53 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

      MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Mr. Lipkins has an accom

      6/10/25 8:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

      MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi

      1/11/22 6:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

      MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which

      11/10/21 6:00:00 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      4/10/24 5:16:36 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/12/24 9:26:34 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • Broadrick Dale bought $162,255 worth of shares (120,000 units at $1.35), increasing direct ownership by 37% to 447,045 units (SEC Form 4)

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/9/24 8:00:31 AM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Rosa David A

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:33:37 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form 4 filed by Director Williams Patrick F.

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:31:06 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form 4 filed by Director Kukekov Nickolay V.

      4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

      2/19/25 4:29:24 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    SEC Filings

    See more
    • BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

      6/13/25 8:31:05 AM ET
      $BRTX
      Managed Health Care
      Health Care
    • SEC Form 10-Q filed by BioRestorative Therapies Inc.

      10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)

      5/14/25 4:30:22 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

      5/14/25 4:11:19 PM ET
      $BRTX
      Managed Health Care
      Health Care

    $BRTX
    Financials

    Live finance-specific insights

    See more
    • BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, the Company's Chief Executive Officer. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and we see many potential value e

      5/14/25 4:05:00 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

      MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. First Quarter 2025 Results Conference Call Details: Date:Wednesday, May 14, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:924151   The call will also

      5/8/25 4:30:00 PM ET
      $BRTX
      Managed Health Care
      Health Care
    • BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

      MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. "2024 was a transformative year for BioRestorative, highlighted by significantly improved financial performance and meaningful clinical program advancement," said Lance Alstodt, BioRestorative's Chief Executive Officer. "Looking ahead, we remain focused on aggressively executing our growth strategy, and very much look forward to updating investors as we progr

      3/27/25 4:05:00 PM ET
      $BRTX
      Managed Health Care
      Health Care